Last Updated : May 10, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Do not list | Complete | ||
| Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Withdrawn | |||
| Folotyn | Pralatrexate | Peripheral T-Cell Lymphoma (PTCL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Firdapse | amifampridine phosphate | Lambert-Eaton Myasthenic Syndrome, adults | Reimburse with clinical criteria and/or conditions | Complete | ||
| Firazyr | icatibant | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Firazyr | Icatibant | Hereditary angioedema | List with clinical criteria and/or conditions | Complete | ||
| Finacea | Azelaic acid | Rosacea | List | Complete | ||
| Fibristal | ulipristal acetate | Uterine fibroids (signs and symptoms) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Fibristal | ulipristal acetate | Uterine fibroids (signs and symptoms) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Fibristal | Ulipristal acetate | Uterine fibroids | List with criteria/condition | Complete |
Last Updated : May 10, 2024